Burzynski Research Institute Inc., a company dedicated to the research and development of Antineoplaston drugs for cancer treatment, has released its Form 10-Q report for the third quarter of fiscal year 2023. The report highlights significant financial and operational developments, including the impact of an FDA clinical hold on its trials, increased operating expenses, and a new license agreement.
Financial Highlights
- Net Loss: $433,015 for the three months ended November 30, 2023, compared to $252,639 for the same period in 2022, primarily due to an increase in research and development costs and general and administrative expenses.
- Net Loss: $972,524 for the nine months ended November 30, 2023, compared to $700,294 for the same period in 2022, driven by increased facility and equipment costs and legal expenses related to clinical holds.
- Basic and Diluted Loss Per Common Share: $(0.00) for the three months ended November 30, 2023, consistent with the same period in 2022.
- Basic and Diluted Loss Per Common Share: $(0.01) for the nine months ended November 30, 2023, consistent with the same period in 2022.
Business Highlights
- Research and Development Focus: The company is primarily engaged in research and development of Antineoplaston drugs for cancer treatment. The clinical trials are currently under a full clinical hold by the FDA, impacting the ability to enroll new patients.
- Clinical Hold Impact: The FDA has placed a full clinical hold on the company's IND 43742, affecting both Phase II and Phase III clinical trials. This hold is due to unresolved issues related to manufacturing deficiencies and adverse events reported in previous trials.
- License Agreement Developments: A new License Agreement was entered into on May 22, 2023, granting the company exclusive rights in the U.S. and Canada to exploit Antineoplaston-related products and services. This agreement is contingent upon FDA approval, which has not yet been granted.
- Operational Dependency: The company's operations are heavily dependent on funding from Dr. Burzynski's medical practice. This economic dependency poses a risk to ongoing operations if such funding were to cease.
- Increased Operating Expenses: There has been a significant increase in general and administrative expenses due to legal and professional costs associated with addressing the FDA's clinical hold and patent-related developments.
- Future Outlook: The company anticipates spending approximately $250,000 in the remaining quarter of the fiscal year ending February 29, 2024. The continuation of operations is reliant on Dr. Burzynski's ongoing financial support under the Research Funding Agreement.
SEC Filing: